Radiation Exposure Rate Values in Nuclear Medicine
The provided evidence does not contain specific dose-rate values at 1 meter for the requested radiopharmaceuticals, but I can provide the available data from the evidence and FDA labels.
Available Dose Rate Data
Diagnostic Radiopharmaceuticals
¹⁸F-FDG (Fluorine-18 FDG)
- At point of injection (typical 370 MBq/10 mCi dose): Maximum dose rate approximately 780 μSv/h at contact, decreasing to approximately 78 μSv/h at 0.5 m 1
- At 1.0 meter: Dose rates fall below 7.5 μSv/h for diagnostic procedures 2
- The effective dose equivalent is 0.027 mSv/MBq 3
- After 2 hours post-injection, dose rates decrease to approximately 1/3 of initial values 1
⁹⁹mTc (Technetium-99m, typical 700 MBq dose)
- At contact: Maximum dose rate approximately 250 μSv/h 1
- At 0.5 m: Approximately 25 μSv/h 1
- At 1.0 m: Below 7.5 μSv/h 2
- After 2 hours, dose rates decrease to approximately 1/3 of initial values 1
- Gamma ray constant: 0.78 R/mCi-hr at 1 cm 4
¹²³I (Iodine-123, typical 370 MBq dose)
- At contact: Maximum dose rate approximately 132 μSv/h 1
- At 0.5 m: Dose rates decrease by approximately one order of magnitude
- After 2 hours, dose rates decrease to approximately 1/2 of initial values 1
- Gamma factor at 1.0 m: 0.721 μSv/h/MBq (with only 1% difference from published standards) 5
¹¹¹In (Indium-111, typical 185 MBq dose)
- At contact: Maximum dose rate approximately 150 μSv/h 1
- After 2 hours, dose rates remain in the same order of magnitude due to longer half-life 1
Therapeutic Radiopharmaceuticals
¹³¹I (Iodine-131)
- No specific dose-rate values at 1 meter are provided in the evidence for therapeutic doses
- The evidence focuses on PRRNT protocols rather than external dose rates
⁹⁰Y (Yttrium-90)
- Administered activities for PRRNT: 2.78–4.44 GBq (75–120 mCi) or 3.7 GBq/m² body surface 6
- No specific external dose-rate measurements at 1 meter provided in the evidence
- ⁹⁰Y is a pure beta emitter with minimal external radiation hazard
¹⁷⁷Lu (Lutetium-177)
- Administered activities for PRRNT: 5.55–7.4 GBq (150–200 mCi) 6
- No specific external dose-rate measurements at 1 meter provided in the evidence
Important Clinical Context
Self-Attenuation Factors
- Patient body attenuation significantly reduces external dose rates. For ¹⁸F-FDG, the average self-attenuation factor is 0.71 ± 0.04, meaning the patient's body absorbs approximately 29% of the radiation 5
- Point source calculations overestimate actual exposure at clinical distances 5
Time-Dependent Decay
- Dose rates decrease with both physical decay and biological clearance
- Effective half-lives for diagnostic procedures range from 1.18 to 11.41 hours 7
- For therapeutic procedures with ⁹⁰Y and ¹⁷⁷Lu, the first 2 days post-administration show the highest urinary excretion 6
Radiation Safety Implications
- At 1.0 m distance, cumulative radiation doses from diagnostic procedures are considerably lower than ICRP limits (1.0 mSv for general public, 5.0 mSv for family members/caregivers) 7
- Nuclear medicine staff exposure per patient ranges from 0.002-0.004 mSv/patient for PET/CT procedures 8
- No special precautionary measures are required after diagnostic nuclear medicine procedures based on measured dose rates 7
Key Limitations
The evidence provided primarily addresses radiation safety protocols and administered activities rather than comprehensive dose-rate tables at standardized distances. For precise dose-rate calculations at 1 meter for specific activities, refer to gamma factors and apply inverse square law corrections with appropriate self-attenuation factors 5.